DC7627 |
EHT-1864
Featured
|
EHT 1864 is a potent Rac family GTPase inhibitor with Kd of 40 nM, 50 nM, 60 nM and 250 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. |
|
DC11287 |
EHT 5372
Featured
|
EHT 5372 is a novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro. |
|
DC7930 |
EI-1
Featured
|
EI1 is a potent and selective small molecule inhibitor of EZH2 with IC50 values of 15 nM and 13 nM for wild type EZH2 and EZH2 Y641F mutant, respectively. |
|
DC12233 |
Eicosadienoic acid
Featured
|
Eicosadienoic acid is a rare, naturally occurring n-6 polyunsaturated fatty acid found mainly in animal tissues. |
|
DC20371 |
eIF4A3 inhibitor 53a |
eIF4A3 inhibitor 53a is a potent, selective and cell-active eukaryotic initiation factor 4A3 (eIF4A3) inhibitor with IC50 of 0.26 uM, SPR Kd of 43 nM. |
|
DC20062 |
eIF4A3-IN-2 |
eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM. |
|
DC9684 |
EL102
Featured
|
EL-102 is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade. |
|
DC10208 |
Elacestrant S enantiomer |
Elacestrant S enantiomer is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. |
|
DC10032 |
Elagolix sodium
Featured
|
Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. |
|
DC7407 |
Elagolix
Featured
|
Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. |
|
DC22394 |
Elaiophylin |
Elaiophylin (Gopalamicin. |
|
DC22182 |
Elatol |
Elatol (NSC 341593) is a specific inhibitor of ATP hydrolysis by eIF4A1 in vitro with broad activity against multiple tumor types. |
|
DC9295 |
Elbasvir(MK-8742)
Featured
|
Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection. |
|
DCAPI1410 |
Eldecalcitol
Featured
|
Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficaci |
|
DC9980 |
Eleclazine(GS-6615)
Featured
|
Eleclazine(GS-6615) is a selective late sodium current inhibitor. |
|
DC21774 |
Eletriptan |
Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist. |
|
DC9291 |
Eliglustat hemitartrate (Genz-112638)
Featured
|
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase. |
|
DC9290 |
Eliglustat(Genz-99067)
Featured
|
Eliglustat is a specific and potent inhibitor of glucosylceramide synthase. |
|
DC7786 |
ELN 441958
Featured
|
ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1] |
|
DC10740 |
ELN484228
Featured
|
ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease. |
|
DC7779 |
ELND0006 |
ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease. |
|
DCAPI1504 |
Elocalcitol |
Elocalcitol |
|
DC20268 |
ELQ300
Featured
|
ELQ300 is a novel inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain). |
|
DCAPI1196 |
Eltrombopag (SB-497115-GR)
Featured
|
Eltrombopag (SB-497115-GR) |
|
DC8369 |
Eltrombopag olamine
Featured
|
Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. |
|
DC23523 |
Elubrixin tosylate |
Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist. |
|
DC21618 |
Elubrixin |
Elubrixin (SB-656933, GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist. |
|
DC8625 |
Eluxadoline Dihydrochloride
Featured
|
Eluxadoline Dihydrochloride is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist. |
|
DC4235 |
Elvitegravir(GS9137)
Featured
|
Elvitegravir (EVG) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. |
|
DC21465 |
EMA300 |
EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain.. |
|